Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus
A Phase 2, Clinical Pharmacological Study of ASP1941 in Japanese Patients With Type 1 Diabetes Mellitus
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Werkelijk)
Inschrijving
Fase
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
-
Aichi, Japan
- Site JP00006
-
Fukuoka, Japan
- Site JP00002
-
Gunma, Japan
- Site JP00009
-
Ibaraki, Japan
- Site JP00001
-
Kanagawa, Japan
- Site JP00008
-
Kanagawa, Japan
- Site JP00005
-
Okayama, Japan
- Site JP00003
-
Osaka, Japan
- Site JP00004
-
Osaka, Japan
- Site JP00010
-
Osaka, Japan
- Site JP00011
-
Tokyo, Japan
- Site JP00007
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
At the time of obtaining informed consent:
- Subject is diagnosed with type 1 diabetes mellitus and has been treated with insulin therapy for at least 52 weeks (364 days).
- Subject is able to be admitted to the site as scheduled.
- Subject is able to record in Patient's diary from the first study drug dose in observation period until the day before the end of post observation.
At screening period:
- Subject has an HbA1c (NGSP) value of between 7.5% and 10.0%. If subject has an HbA1c value of between 7.3% and 10.2% (out of the reference range), HbA1c may be re-measured only once within the allowance range in screening period. Re-measured HbA1c (NGSP) value will be adopted for the determination.
- Subject has been receiving insulin therapy at daily doses (instructed by a doctor) within a ±20% range for at least 12weeks (83days) prior to the start of screening.
- Subject has a fasting serum C-peptide level ≤0.5 ng/mL at screening.
- Subject receives treatments for complications (except for transient diseases such as a cold) that, in the investigator's or sub-investigator's opinion, need not to be changed during the period from the start of screening to the end of the treatment period.
- Subject has body mass index (BMI) value of 20.0 to 35.0 kg/m2 at screening.
Exclusion Criteria:
At the time of obtaining informed consent:
- Subject has type 2 diabetes mellitus.
- Subject has participated or has been participating in a clinical study or a post marketing study of another drug or medical equipment within 12 weeks (84 days) prior to obtaining informed consent.
- Subject has received ASP1941 (ipragliflozin) with the exception of placebo.
At screening period:
- Subject has proliferative retinopathy (subjects with stable condition after photocoagulation etc. may be enrolled in the study).
- Subject has developed hypoglycemia unawareness (requires help of a third person) or severe hypoglycemia (diabetic coma, precoma, or convulsion) within 12 weeks (84 days) prior to the start of screening.
- Subject has developed diabetic ketoacidosis within 12 weeks (84 days) prior to the start of screening.
- Subject has chronic disease(s) which require the continuous use of corticosteroids or immunosuppressants (oral administration, injection, inhalation, or suppository).
- Subject has received hypoglycemic agent(s) other than insulin within 12 weeks (83 days) prior to the start of screening.
- Subject with perioperative, severe infection or serious injury.
- Subject whose serum creatinine value exceeds the upper limit of normal range at screening.
- Subject has a urinary albumin/urinary creatinine ratio>300 mg/g in urinalysis at screening.
- Subject has a history of clinically significant renal disease(s) such as renovascular occlusive disease, nephrectomy, and/or renal transplant.
- Subject has AST and ALT >2 ×ULN or T-Bil >1.5 × ULN at screening, or has a history of serious hepatic diseases.
- Subject presents with symptoms of dysuria, anuria, oliguria and urinary retention.
- Subject has a history of recurrent urinary tract infections and recurrent genital infections (developed 3 times or more within 24 weeks (168 days) prior to the start of screening).
- Subject has urinary tract infection or genital infection with subjective symptoms.
- Subject has a history of angina unstable, myocardial infarction, angioplasty, and serious heart disease (NYHA Class II-IV) within 24 weeks (168 days) prior to the start of screening, or has complications of heart disease that, in the investigator's or sub-investigator's opinion, may interfere with the evaluation of safety of ASP1941.
- Subject has uncontrolled blood pressure (systolic blood pressure≥160 mmHg or diastolic blood pressure≥100 mmHg in the supine position after a 5-minute rest at screening ).
- Subject has serious gastrointestinal disease or a history of serious gastrointestinal operation.
- Subject has malignant tumors concomitantly (subject may be enrolled in the study if the subject has a history of a malignant tumor which has not recurred without any treatment within 5 years prior to the start of screening).
- Subject has psychiatric disorder that makes the subject unsuitable for study participation.
- Subject has drug addiction or alcohol abuse.
- Subject has a history of drug allergies.
- Subject is unable to adhere to any of the compliance such as hospital visits and dose instruction specified in this study, or does not agree with it.
- Subject has donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or blood components within 14 days prior to the start of screening.
- Subject has any condition that, in the investigator's or sub-investigator's opinion, makes the subject unsuitable for study participation.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Placebo-vergelijker: Placebo
een keer per dag
|
Mondeling
|
|
Experimenteel: ASP1941 Low dose group
once daily
|
Mondeling
Andere namen:
|
|
Experimenteel: ASP1941 Middle dose group
once daily
|
Mondeling
Andere namen:
|
|
Experimenteel: ASP1941 High dose group
once daily
|
Mondeling
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Daily profile of plasma glucose levels
Tijdsspanne: up to Day 14
|
up to Day 14
|
|
|
Area under the concentration-time curve (AUC) 0-24hr (AUC0-24h) of plasma glucose levels
Tijdsspanne: at Day -1, Day 1 and Day 14
|
at Day -1, Day 1 and Day 14
|
|
|
AUC0-3h of plasma glucose levels
Tijdsspanne: at Day -1, Day 1 and Day 14
|
at Day -1, Day 1 and Day 14
|
|
|
AUC0-4h of plasma glucose levels
Tijdsspanne: up to Day 14
|
up to Day 14
|
|
|
AUC0-10h of plasma glucose levels
Tijdsspanne: up to Day 14
|
up to Day 14
|
|
|
Fasting plasma glucose levels
Tijdsspanne: up to Day 21
|
up to Day 21
|
|
|
Glycoalbumin
Tijdsspanne: up to Day 21
|
up to Day 21
|
|
|
Urinary glucose excretion
Tijdsspanne: up to Day 14
|
up to Day 14
|
|
|
Urinary glucose excretion rate
Tijdsspanne: up to Day 14
|
up to Day 14
|
|
|
Urine volume
Tijdsspanne: up to Day 14
|
up to Day 14
|
|
|
Urinary glucose concentration
Tijdsspanne: up to Day 15
|
up to Day 15
|
|
|
Body weight
Tijdsspanne: up to Day 21
|
up to Day 21
|
|
|
Renal glucose clearance
Tijdsspanne: up to Day 14
|
up to Day 14
|
|
|
Plasma concentration of unchanged ASP1941
Tijdsspanne: up to Day 14
|
up to Day 14
|
|
|
Urinary concentration of unchanged ASP1941
Tijdsspanne: up to Day 14
|
up to Day 14
|
|
|
Pharmacokinetics (PK) parameter of ASP1941 in plasma: AUC from time 0 extrapolated to infinity (AUCinf)
Tijdsspanne: at Day 1
|
at Day 1
|
|
|
PK parameter of ASP1941 in plasma: AUC from the time of dosing to the last measurable concentration (AUClast)
Tijdsspanne: at Day 1 and Day 14
|
at Day 1 and Day 14
|
|
|
PK parameter of ASP1941 in plasma: AUC from the time of dosing to 24 hr (AUC0-24h)
Tijdsspanne: at Day 1 and Day 14
|
at Day 1 and Day 14
|
|
|
PK parameter of ASP1941 in plasma: Oral Clearance (CL/F)
Tijdsspanne: at Day 1 and Day 14
|
at Day 1 and Day 14
|
|
|
PK parameter of ASP1941 in plasma: Maximum concentration (Cmax)
Tijdsspanne: at Day 1 and Day 14
|
at Day 1 and Day 14
|
|
|
PK parameter of ASP1941 in plasma: Terminal Elimination Half-life (t1/2)
Tijdsspanne: at Day 1 and Day 14
|
at Day 1 and Day 14
|
|
|
PK parameter of ASP1941 in plasma: Time of the Maximum Concentration (tmax)
Tijdsspanne: at Day 1 and Day 14
|
at Day 1 and Day 14
|
|
|
PK parameter of ASP1941 in urine: Amount excreted in urine between time (Ae)
Tijdsspanne: at Day 1 and Day 14
|
at Day 1 and Day 14
|
|
|
PK parameter of ASP1941 in urine: % of the dose of excreted in urine (Ae%)
Tijdsspanne: at Day 1 and Day 14
|
at Day 1 and Day 14
|
|
|
PK parameter of ASP1941 in plasma and urine: Renal Clearance (CLr)
Tijdsspanne: at Day 1 and Day 14
|
at Day 1 and Day 14
|
|
|
Safety assessed by vital signs
Tijdsspanne: up to Day 21
|
Supine blood pressure and supine pulse rate
|
up to Day 21
|
|
Safety assessed by 12-lead electrocardiogram
Tijdsspanne: up to Day 21
|
up to Day 21
|
|
|
Safety assessed by laboratory tests
Tijdsspanne: up to Day 21
|
Hematology, biochemistry and urinalysis
|
up to Day 21
|
|
Safety assessed by self-monitored blood glucose levels
Tijdsspanne: up to Day 21
|
up to Day 21
|
|
|
Safety assessed by Adverse events
Tijdsspanne: up to Day 21
|
up to Day 21
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Werkelijk)
Primaire voltooiing
Studie voltooiing (Werkelijk)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Glucosemetabolismestoornissen
- Metabole ziekten
- Ziekten van het immuunsysteem
- Auto-immuunziekten
- Endocriene systeemziekten
- Suikerziekte
- Diabetes mellitus, type 1
- Hypoglycemische middelen
- Fysiologische effecten van medicijnen
- Moleculaire mechanismen van farmacologische werking
- Natrium-Glucose Transporter 2-remmers
- Ipragliflozine
Andere studie-ID-nummers
Andere studie-ID-nummers
- 1941-CL-6001
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .